Adoptive cellular therapy: A race to the finish line

Science Translational Medicine

Volumn 7, Issue 280, 2015, Pages

  June, Carl H ^a   Riddell, Stanley R ^b   Schumacher, Ton N ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

CELL SPECIFICITY; CELL THERAPY; CELL TRANSFER; CELLULAR DISTRIBUTION; COST EFFECTIVENESS ANALYSIS; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TOXICITY TESTING; TREATMENT INDICATION; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE TRANSFER; ADVERSE EFFECTS; IMMUNOLOGY;

ADOPTIVE TRANSFER; GENETIC ENGINEERING; HUMANS; T-LYMPHOCYTES;

EID: 84925607772     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa3643     Document Type: Review

References (55)

1. R. E. Billingham, L. Brent, P. B. Medawar, Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc. R. Soc. London Ser. B 143, 58-80 (1954).
2. L. Drujont, L. Carretero-Iglesia, L. Bouchet-Delbos, G. Beriou, E. Merieau, M. Hill, Y. Delneste, M. C. Cuturi, C. Louvet, Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. PLOS ONE 9, e100013 (2014).
3. S. Sattler, G.-S. Ling, D. Xu, L. Hussaarts, A. Romaine, H. Zhao, L. Fossati-Jimack, T. Malik, H. T. Cook, M. Botto, Y. L. Lau, H. H. Smits, F. Y. Liew, F. P. Huang, IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50, 107-122 (2014).
4. S. R. Riddell, M. Elliott, D. A. Lewinsohn, M. J. Gilbert, L. Wilson, S. A. Manley, S. D. Lupton, R. W. Overell, T. C. Reynolds, L. Corey, P. D. Greenberg, T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2, 216-223 (1996).
5. J. Scholler, T. Brady, G. Binder-Scholl, W.-T. Hwang, G. Plesa, K. Hege, A. Vogel, M. Kalos, J. Riley, S. Deeks, R. Mitsuyasu, W. Bernstein, N. Aronson, B. Levine, F. Bushman, C. June, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132Ra153 (2012).
6. Y. C. Ho, L. Shan, N. N. Hosmane, J. Wang, S. B. Laskey, D. I. Rosenbloom, J. Lai, J. N. Blankson, J. D. Siliciano, R. F. Siliciano, Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
7. G. Hütter, D. Nowak, M. Mossner, S. Ganepola, A. Müssig, K. Allers, T. Schneider, J. Hofmann, C. Kücherer, O. Blau, I. W. Blau, W. K. Hofmann, E. Thiel, Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698 (2009).
8. J. J. Rossi, C. H. June, D. B. Kohn, Genetic therapies against HIV. Nat. Biotechnol. 25, 1444-1454 (2007).
9. K. Deng, M. Pertea, A. Rongvaux, L. Wang, C. M. Durand, G. Ghiaur, J. Lai, H. L. McHugh, H. Hao, H. Zhang, J. B. Margolick, C. Gurer, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, S. G. Deeks, T. Strowig, P. Kumar, J. D. Siliciano, S. L. Salzberg, R. A. Flavell, L. Shan, R. F. Siliciano, Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
10. A. M. Lesokhin, M. R. Callahan, M. A. Postow, J. D. Wolchok, On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr1 (2015).
11. N. van Rooij, M. M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L. J. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, M. Nieuwland, M. R. Stratton, R. M. Kerkhoven, C. Kesmir, J. B. Haanen, P. Kvistborg, T. N. Schumacher, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
12. M. M. Gubin, X. Zhang, H. Schuster, E. Caron, J. P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C. D. Arthur, W. J. Krebber, G. E. Mulder, M. Toebes, M. D. Vesely, S. S. Lam, A. J. Korman, J. P. Allison, G. J. Freeman, A. H. Sharpe, E. L. Pearce, T. N. Schumacher, R. Aebersold, H. G. Rammensee, C. J. Melief, E. R. Mardis, W. E. Gillanders, M. N. Artyomov, R. D. Schreiber, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
13. D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
14. C. H. Lamers, R. Willemsen, P. van Elzakker, S. van Steenbergen-Langeveld, M. Broertjes, J. Oosterwijk-Wakka, E. Oosterwijk, S. Sleijfer, R. Debets, J. W. Gratama, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72-82 (2011).
15. M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. C. Chen, J. C. Yang, S. A. Rosenberg, P. Hwu, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
16. J. L. Davis, M. R. Theoret, Z. Zheng, C. H. Lamers, S. A. Rosenberg, R. A. Morgan, Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16, 5852-5861 (2010).
17. L. P. Li, J. C. Lampert, X. Chen, C. Leitao, J. Popović, W. Müller, T. Blankenstein, Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat. Med. 16, 1029-1034 (2010).
18. M. R. Parkhurst, J. C. Yang, R. C. Langan, M. E. Dudley, D. A. Nathan, S. A. Feldman, J. L. Davis, R. A. Morgan, M. J. Merino, R. M. Sherry, M. S. Hughes, U. S. Kammula, G. Q. Phan, R. M. Lim, S. A. Wank, N. P. Restifo, P. F. Robbins, C. M. Laurencot, S. A. Rosenberg, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626 (2011).
19. J. Corrigan-Curay, H. P. Kiem, D. Baltimore, M. O'Reilly, R. J. Brentjens, L. Cooper, S. Forman, S. Gottschalk, P. Greenberg, R. Junghans, H. Heslop, M. Jensen, C. Mackall, C. June, O. Press, D. Powell, A. Ribas, S. Rosenberg, M. Sadelain, B. Till, A. P. Patterson, R. C. Jambou, E. Rosenthal, L. Gargiulo, M. Montgomery, D. B. Kohn, T-cell immunotherapy: Looking forward. Mol. Ther. 22, 1564-1574 (2014).
20. B. J. Cameron, A. B. Gerry, J. Dukes, J. V. Harper, V. Kannan, F. C. Bianchi, F. Grand, J. E. Brewer, M. Gupta, G. Plesa, G. Bossi, A. Vuidepot, A. S. Powlesland, A. Legg, K. J. Adams, A. D. Bennett, N. J. Pumphrey, D. D. Williams, G. Binder-Scholl, I. Kulikovskaya, B. L. Levine, J. L. Riley, A. Varela-Rohena, E. A. Stadtmauer, A. P. Rapoport, G. P. Linette, C. H. June, N. J. Hassan, M. Kalos, B. K. Jakobsen, Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).
21. M. E. Birnbaum, J. L. Mendoza, D. K. Sethi, S. Dong, J. Glanville, J. Dobbins, E. Ozkan, M. M. Davis, K. W. Wucherpfennig, K. C. Garcia, Deconstructing the peptide-MHC specificity of T cell recognition. Cell 157, 1073-1087 (2014).
22. C. J. Voskens, S. M. Goldinger, C. Loquai, C. Robert, K. C. Kaehler, C. Berking, T. Bergmann, C. L. Bockmeyer, T. Eigentler, M. Fluck, C. Garbe, R. Gutzmer, S. Grabbe, A. Hauschild, R. Hein, G. Hundorfean, A. Justich, U. Keller, C. Klein, C. Mateus, P. Mohr, S. Paetzold, I. Satzger, D. Schadendorf, M. Schlaeppi, G. Schuler, B. Schuler-Thurner, U. Trefzer, J. Ulrich, J. Vaubel, R. von Moos, P. Weder, T. Wilhelm, D. Göppner, R. Dummer, L. M. Heinzerling, The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLOS ONE 8, e53745 (2013).
23. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol, Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
24. A. Mirsoian, M. N. Bouchlaka, G. D. Sckisel, M. Chen, C. C. Pai, E. Maverakis, R. G. Spencer, K. W. Fishbein, S. Siddiqui, A. M. Monjazeb, B. Martin, S. Maudsley, C. Hesdorff er, L. Ferrucci, D. L. Longo, B. R. Blazar, R. H. Wiltrout, D. D. Taub, W. J. Murphy, Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 211, 2373-2383 (2014).
25. P. A. McSweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina, D. G. Maloney, T. R. Chauncey, T. A. Gooley, U. Hegenbart, R. A. Nash, J. Radich, J. L. Wagner, S. Minor, F. R. Appelbaum, W. I. Bensinger, E. Bryant, M. E. Flowers, G. E. Georges, F. C. Grumet, H. P. Kiem, B. Torok-Storb, C. Yu, K. G. Blume, R. F. Storb, Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001).
26. J. M. Kaldor, N. E. Day, F. Pettersson, E. A. Clarke, D. Pedersen, W. Mehnert, J. Bell, H. Høst, P. Prior, S. Karjalainen, F. Neal, M. Koch, P. Band, W. Choi, V. P. Kirn, A. Arslan, B. Zarén, A. R. Belch, H. Storm, B. Kittelmann, P. Fraser, M. Stovall, Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322, 1-6 (1990).
27. J. Hataye, J. J. Moon, A. Khoruts, C. Reilly, M. K. Jenkins, Naive and memory CD4+ T cell survival controlled by clonal abundance. Science 312, 114-116 (2006).
28. J. A. Doudna, E. Charpentier, Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
29. H. Kim, J. S. Kim, A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321-334 (2014).
30. E. Provasi, P. Genovese, A. Lombardo, Z. Magnani, P. Q. Liu, A. Reik, V. Chu, D. E. Paschon, L. Zhang, J. Kuball, B. Camisa, A. Bondanza, G. Casorati, M. Ponzoni, F. Ciceri, C. Bordignon, P. D. Greenberg, M. C. Holmes, P. D. Gregory, L. Naldini, C. Bonini, Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807-815 (2012).
31. B. Berdien, U. Mock, D. Atanackovic, B. Fehse, TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Ther. 21, 539-548 (2014).
32. P. Tebas, D. Stein, W. W. Tang, I. Frank, S. Q. Wang, G. Lee, S. K. Spratt, R. T. Surosky, M. A. Giedlin, G. Nichol, M. C. Holmes, P. D. Gregory, D. G. Ando, M. Kalos, R. G. Collman, G. Binder-Scholl, G. Plesa, W. T. Hwang, B. L. Levine, C. H. June, Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910 (2014).
33. H. Torikai, A. Reik, P. Q. Liu, Y. Zhou, L. Zhang, S. Maiti, H. Huls, J. C. Miller, P. Kebriaei, B. Rabinovitch, D. A. Lee, R. E. Champlin, C. Bonini, L. Naldini, E. J. Rebar, P. D. Gregory, M. C. Holmes, L. J. Cooper, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697-5705 (2012).
34. F. S. Hodi, S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
35. S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
36. J. R. Brahmer, S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta, J. M. Wigginton, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
37. P. Zhou, D. R. Shaffer, D. A. Alvarez Arias, Y. Nakazaki, W. Pos, A. J. Torres, V. Cremasco, S. K. Dougan, G. S. Cowley, K. Elpek, J. Brogdon, J. Lamb, S. J. Turley, H. L. Ploegh, D. E. Root, J. C. Love, G. Dranoff, N. Hacohen, H. Cantor, K. W. Wucherpfennig, In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52-57 (2014).
38. A. Di Stasi, B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. Foster, H. E. Heslop, M. K. Brenner, G. Dotti, B. Savoldo, T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392-6402 (2009).
39. G. M. Bendle, C. Linnemann, L. Bies, J. Y. Song, T. N. Schumacher, Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J. Immunol. 191, 3232-3239 (2013).
40. S. P. Kerkar, R. S. Goldszmid, P. Muranski, D. Chinnasamy, Z. Yu, R. N. Reger, A. J. Leonardi, R. A. Morgan, E. Wang, F. M. Marincola, G. Trinchieri, S. A. Rosenberg, N. P. Restifo, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757 (2011).
41. X. Wang, W. C. Chang, C. W. Wong, D. Colcher, M. Sherman, J. R. Ostberg, S. J. Forman, S. R. Riddell, M. C. Jensen, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011).
42. B. Philip, E. Kokalaki, L. Mekkaoui, S. Thomas, K. Straathof, B. Flutter, V. Marin, T. Marafioti, R. Chakraverty, D. Linch, S. A. Quezada, K. S. Peggs, M. Pule, A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood 124, 1277-1287 (2014).
43. C. Berger, M. E. Flowers, E. H. Warren, S. R. Riddell, Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294-2302 (2006).
44. A. Di Stasi, S. K. Tey, G. Dotti, Y. Fujita, A. Kennedy-Nasser, C. Martinez, K. Straathof, E. Liu, A. G. Durett, B. Grilley, H. Liu, C. R. Cruz, B. Savoldo, A. P. Gee, J. Schindler, R. A. Krance, H. E. Heslop, D. M. Spencer, C. M. Rooney, M. K. Brenner, Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
45. G. M. Bendle, C. Linnemann, A. I. Hooijkaas, L. Bies, M. A. de Witte, A. Jorritsma, A. D. Kaiser, N. Pouw, R. Debets, E. Kieback, W. Uckert, J. Y. Song, J. B. Haanen, T. N. Schumacher, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570, 1p, 570 (2010).
46. H. Torikai, A. Reik, F. Soldner, E. H. Warren, C. Yuen, Y. Zhou, D. L. Crossland, H. Huls, N. Littman, Z. Zhang, S. S. Tykodi, P. Kebriaei, D. A. Lee, J. C. Miller, E. J. Rebar, M. C. Holmes, R. Jaenisch, R. E. Champlin, P. D. Gregory, L. J. Cooper, Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341-1349 (2013).
47. + T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
48. P. F. Robbins, Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, Y. Samuels, S. A. Rosenberg, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
49. N. P. Restifo, L. Gattinoni, Lineage relationship of effector and memory T cells. Curr. Opin. Immunol. 25, 556-563 (2013).
50. + T cells. Science 340, 635-639 (2013).
51. + T cell immunity. Science 340, 630-635 (2013).
52. C. Berger, D. Sommermeyer, M. Hudecek, M. Berger, A. Balakrishnan, P. J. Paszkiewicz, P. L. Kosasih, C. Rader, S. R. Riddell, Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol. Res. 2, 206-216 (2015).
53. C. C. Kloss, M. Condomines, M. Cartellieri, M. Bachmann, M. Sadelain, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71-75 (2013).
54. W. Peng, G. Lizée, P. Hwu, Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. OncoImmunology 2, e22691 (2013).
55. R. C. Koya, S. Mok, N. Otte, K. J. Blacketor, B. Comin-Anduix, P. C. Tumeh, A. Minasyan, N. A. Graham, T. G. Graeber, T. Chodon, A. Ribas, BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72, 3928-3937 (2012).